The Global chlorpheniramine maleate market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The high incidence of allergic conditions such as rhinitis has been attributed to the positive growth of the market. Chlorpheniramine maleate is an alkylamine antihistamine that is used in the treatment of allergic conditions such as rhinitis and urticaria. This compound blocks histamine during allergic reactions, thus preventing allergic symptoms namely runny nose, watery eyes, sneezing, and itching. Moreover, the high demand for over-the-counter (OTC) products and the development of healthcare infrastructure further propel market growth. However, factors such as side effects associated with the use of antihistamines and lack of awareness about allergic reactions amongst people are expected to hinder the market growth. The introduction of novel therapies by R&D with fewer side effects and more efficacy provide opportunities in near future.
The market is segmented on the basis of dosage form, application, and region. On the basis of the dosage form, the market is segmented into injection, syrup, tablets, and powder, and others, which include granules for the solution and liquid-filled capsules. Based on the application, the market is divided into allergy, hay fever, common cold, itchy throat/skin. On the basis of end-user, the market is categorized into hospitals, clinics, and research institutes.
Market Coverage
Competitive Landscape: AstraZeneca PLC, GlaxoSmithKline plc, Merck KGaA, and Sanofi S.A., among others.
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
Global Chlorpheniramine Maleate Market Report Segmentation
By Dosage Form
• Injection
• Syrup
• Tablets
• Powder
• Others
By Application
• Allergy
• Hay Fever
• Common Cold
• Itchy Throat/Skin
By End-User
• Hospitals
• Clinics
• Research Institutes
Global Chlorpheniramine Maleate Market by Region
North America
Europe
Asia-Pacific